Strategies for an oral vaccine against Helicobacter pylori

Current Opinion in Gastroenterology

Volumn 12, Issue 6, 1996, Pages 564-568

  Ferrero, Richard L ^a   Labigne, Agnes ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE;

BACTERIAL IMMUNITY; CHRONIC GASTRITIS; HELICOBACTER PYLORI; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PREVALENCE; REVIEW; STOMACH CARCINOGENESIS;

EID: 0029830239     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199611000-00013     Document Type: Review

References (43)

1. Marshall BJ: Helicobacter pylori: the etiologic agent for peptic ulcer. JAMA 1995, 274:1064-1066.
2. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995, 33:984-991.
3. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995, 333:32-41.
4. Mitchell HM, Li YY, Hu PJ, Liu Q, Chen M, Du GG, Wang ZJ, Lee A, Hazell SL: Epidemiology of Helicobacter pylori in Southern China: identification of early childhood as the critical period for acquisition. J Infect Dis 1992, 166:149-153.
5. Blaser MJ, Chyou PH, Nomura A: Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995, 55:562-565.
6. Chen M, Lee A, Hazell SL: Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet 1992, 339:1120-1121.
7. Czinn SJ, Cai A, Nedrud JG: Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993, 11:637-642.
8. Marchetti M, Aricò B, Burroni D, Figura N, Rappuoli R, Ghiara P: Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995, 267:1655-1658.
9. Kleanthous H, Tibbits T, Bakios TJ, Georgopoulos K, Myers G, Ermak TH, Fox J, Monath T: In vivo selection of a highly adapted H. pylori isolate and the development of an H. pylori mouse model for studying vaccine efficacy and attenuating lesions [abstract]. Gut 1995, 37:94.
10. McColm AA, Bagshaw JA, O'Malley CO, McLaren A: Development of a mouse model of gastric colonisation with Helicobacter pylori [abstract]. Gut 1995, 37:50.
11. Radcliff FJ, Chen M, Lee A: Protective immunisation against Helicobacter spp stimulates long term immunity [abstract]. Gut 1995, 37(suppl 1):48. In this abstract, it was reported that long-term anti-Helicobacter immunity (16 months) was induced in immunized mice. This suggests that immunologic memory can be stimulated in the gastric mucosa.
12. Doidge C, Gust I, Lee A, Buck F, Hazell S, Manne U: Therapeutic immunization against helicobacter infection. Lancet 1994, 343:914-915.
13. Glauser MH, Michetti P, Blum AL, Corthésy-Theulaz I: Carbon 14-urea breath test as a non-invasive method to monitor Helicobacter felis infection in mice. Digestion 1996, 57:30-34.
14. Ferrero RL, Labigne A: Cloning, expression and sequencing of Helicobacter felis urease genes. Mol Microbiol 1993, 9:323-333.
15. Eaton KA, Krakowka S: Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun 1994, 62:3604-3607.
16. Michetti P, Corthésy-Theulaz I, Davin C, Haas R, Vaney A-C, Hertz M, Bille J, Kraehenbuhl J-P, Saraga E, Blum AL: Immunization of Balb/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 1994, 107:1002-1011.
17. Lee CK, Weltzin R, Thomas WD Jr, Kleanthous H, Ermak TE, Soman G, Hill JE, Ackerman SK, Monath TP: Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995, 172:161-172. A comprehensive study that showed that oral immunization of mice with as little as 5 μg of recombinant H. pylori urease, together with E. coli LT as the mucosal adjuvant, was sufficient to prevent H. felis infection in the animals. Moreover, the authors investigated systemic and local antibody responses with respect to protection status and reported that secretory IgA levels correlated with protection.
18. Cuenca R, Blanchard T, Lee C, Monath T, Redline R, Nedrud J, Czinn S: Therapeutic immunization against Helicobacter mustelae infection in naturally infected ferrets [abstract]. Gastroenterology 1995, 108:191.
19. Kreiss C, Buclin T, Cosma M, Corthésy-Theulaz I, Michetti P: Safety of oral immunization with recombinant urease in patients with Helicobacter pylori infection [letter]. Lancet 1996, 347:1630-1631. This letter reports on a double-blind phase I clinical study in which 12 healthy adults with asymptomatic H. pylori infection were given either 60 mg of recombinant H. pylori urease or placebo once weekly for 4 weeks. Gastroscopy was performed at the beginning of the trial and 1 month after the final dose of urease or placebo. No significant differences in gastric disease were observed between the two groups, suggesting that oral immunization with urease was well tolerated. These results have fundamental importance for the development of an H. pylori vaccine.
20. Ferrero RL, Thiberge J-M, Huerre M, Labigne A: Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun 1994, 62:4981-4989.
21. Doré-Davin C, Michetti P, Saraga E, Blum AL, Corthésy-Theulaz I: A 37 kDa fragment of UreB is sufficient to confer protection against Helicobacter felis infection in mice. Gastroenterology 1996, in press.
22. Blanchard TG, Czinn SJ, Maurer R, Thomas WD, Soman G, Nedrud JG: Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect Immun 1995, 63:1394-1399.
23. Corthésy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney A-C, Haas R, Kraehenbuhl J-P, Blum AL, Michetti P: Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995, 109:115-121. These authors present data that extend the findings of previous studies of therapeutic immunization using whole-cell sonicates. In this paper, it was shown that immunization with the UreB subunit of H. pylori urease and cholera toxin was sufficient to clear H. felis infection in 56% of mice and that clearance was accompanied by the absence of body gastritis. Significantly, 9 of 14 mice in which the infection had been eradicated were immune to a subsequent challenge.
24. Kansau I, Labigne A: Heat shock proteins of Helicobacter pylori. Aliment Pharmacol Ther 1996, 10(suppl 1):51-56.
25. Ferrero RL, Thiberge J, Kansau I, Wuscher N, Huerre M, Labigne A: The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A 1995, 92:6499-6503. In this study, the HSP homologues of H. pylori (HspA and HspB) were shown to be protective antigens in the H. felis mouse model. This was the first report in which a protein belonging to the GroES family (H. pylori HspA) was shown to be effective as a protective antigen. It was also shown that coadministration of HspA with H. pylori UreB provided a protective efficacy statistically comparable to that of whole-cell sonicates. Induction of protective immunity appeared to correlate with consistently high antigen-specific IgG1 responses in the sera of mice.
26. Mustafa AS, Lundin KEA, Meloen RH, Shinnick TM, Coulson AFW, Oftung F: HLA-DR4-restricted T-cell epitopes from the mycobacterial 60,000 MW heat shock protein (hsp 60) do not map to the sequence of homology regions with the human hsp 60. Immunology 1996. 87:421-427.
27. Karopoulos C, Rowley MJ, Handley CJ, Strugnell RA: Antibody reactivity to mycobacterial 65 kDa shock protein: Relevance to autoimmunity. J Autoimmun 1995, 8:235-248.
28. Cover TL: The vacuolating cytotoxin of Helicobacter pylori. Mol Microbiol 1996, 20:241-246.
29. Manetti R, Massari P, Burroni D, De Bernard M, Marchini A, Olivieri R, Papini E, Montecucco C, Rappuoli R, Telford JL: Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infect Immun 1995, 63:4476-4480.
30. Keenan J, Allardyce RA, Bagshaw P: Helicobacter felis surface antigens serve as protective targets in orally immunised mice [abstract]. Gut 1995, 37:93.
31. Odenbreit S, Till M, Haas R: Optimized BlaM-transopson shuttle mutagenesis of Helicobacter pylori allows the identification of novel genetic loci involved in bacterial virulence. Mol Microbiol 1996, 20:361-373.
32. Fontana MR, Manetti R, Giannelli V, Magagnoli C, Marchini A, Olivieri R, Domenighini M, Rappuoli R, Pizza M: Construction of nontoxic derivalives of cholera toxin and characterization of the immunological response against the A subunit. Infect Immun 1995, 63:2356-2360.
33. Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M, Rappouli R, Dougan G: Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A 1995, 92:1644-1648.
34. Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, Abrignani S, Douce G, De Magistris MT: Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant Infect Immun 1996, 64:974-979.
35. Ghiara P, Michetti P: Development of a vaccine. Curr Opin Gastroenterol 1995, 11:52-56.
36. Rehnberg-Laiho L, Marnila P, Kosunen TU, Syvaoja E-L, Hanninen M-L, Karkkainen P, Rautelin H, Virtanen S, Lilius E-M, Korhonen H: Specific immune colostrum in the prevention of Halicobacter infection in mice [abstract]. Gut 1995, 36:92.
37. Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross TM, Tompkins DS, Rathbone BJ: Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991, 338:332-335.
38. Hayashi S, Sugiyama T, Hisano K, Awakawa T, Kurokawa I, Yachi A, Isogai H, Isogai E, Yokota K, Hirai Y, Oguma K, Fujii N: Quantitative detection of secretory immunoglobulin A to Helicobacter pylori in gastric juice: antibody capture enzyme-linked immunosorbent assay. J Clin Lab Anal 1996, 10:74-77.
39. Fox JG, Blanco M, Murphy JC, Taylor NS, Lee A, Kabok Z, Pappo J: Local and systemic immune responses in murine Helicobacter felis active chronic gastritis. Infect Immun 1993, 61:2309-2315.
40. Pappo J, Thomas WD Jr, Zabok Z, Taylor NS, Murphy JC, Fox JG: Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect Immun 1995, 63:1246-1252.
41. Mohammadi M, Redline R, Nedrud J, Czinn S: Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains. Infect Immun 1996, 64:238-245. A fascinating study in which different strains of mice were infected with a single strain of H. felis. The authors reported that the severity and type of pathologic disorders observed in the infected mice varied according to the genetic background of the host. The data supported the suggestion that host properties are major contributing factors in the outcome of Helicobacter infection.
42. Enno A, O'Rourke JL, Howlett CR, Jack A, Dixon MF, Lee A: MALTomalike lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. Am J Pathol 1995, 147:217-222. These authors showed that H. felis infection in Balb/c mice induced the formation of gastric lesions that resembled human B-cell lymphomas. This paper provides evidence of a causal link between Helicobacter infection and gastric lymphoma formation.
43. Ernst PB, Crowe SE, Reyes VE: The immunopathogenesis of gastroduodenal disease associated with Helicobacter pylori infection. Curr Opin Gastroenterol 1995, 11:512-518. An extensive review of the immunologic responses induced by H. pylori infection, as well as a discussion of the putative differences between the immunologic mechanisms associated with infection and those induced by immunization.